抗肝癌中药古方用药规律统计及抗肝癌新药研发风险评估  

Regularity of drugs compatibility of anti-hepatoma traditional Chinese medicine ancient prescriptions and Risk evaluation of anti-hepatoma new drug research and development

作　　者：张靖[1] 李红法[1] 樊威[2] 刘振[1] 满淑丽[2] 司书勇 高文远[1] 

机构地区：[1]天津大学药物科学与技术学院,天津300072 [2]天津科技大学生物工程学院,天津300457 [3]北京工业大学计算机学院,北京100124

出　　处：《中国中药杂志》2014年第19期3870-3875,共6页China Journal of Chinese Materia Medica

摘　　要：抗肝癌中药古方应用历史悠久,其药物配伍科学、合理,历经检验,是现代新药研发的宝贵财富。新药研发投资大、周期长、风险高,尤其是抗肿瘤药物的研发,比其他药物的开发面临更多的风险,成功率更低。该文采用计算机编写程序统计出124个抗肝癌古方中药物配伍规律,为抗肝癌新药开发提供帮助,降低药物筛选的风险。该文同时采用风险评估方法中的定性分析法,通过向北京、上海、天津等6个地区的22家药物研发、生产、销售单位发放240份关于抗肝癌新药研发项目风险评估的调查问卷,了解在抗肝癌新药研发过程中哪些风险对研发、生产、销售产生重要影响,从而为抗肝癌新药研发人员提供参考,进而有针对的采取防控措施,以降低研发风险,提高研发成功率。Traditional Chinese ancient prescriptions have been used for treatment of liver cancerfor a long history and the scientific and rational eompatibilityis a great wealth for modem research and development （R＆D） of new drugs. The research and development of new drugs are often accompanied with a large investment, a long cycle and a high risk, especially for the anti-tumor drugs R＆D which are facing more risks and lower successful rate. In this research, the regularity of compatibility of drags was analyzed from 124 anti-hepatoma ancient prescriptions by computer program. The results can offer help to the R＆D of anti-hepatoma new drags and reduce the risk of drug screening. In addition, we surveyed 22 companies in this field from six provinces such as Beijing, Shanghai, Tianjin and so on and obtained 240 risk assessment questionaires. Then we used qualitative analysis method to interpret the greatest impacts for the risks in the process of R＆D, production and sales of anti-hepatoma new drags. The study provides a basis for anti-liver cancer drags R＆D researchers, who can take effective measures to reduce the R＆D risks and improve successful rate.

关 键 词：中药古方 用药规律 抗肝癌新药 研发 风险评估 

分 类 号：R288[医药卫生—中药学]